The nature of amyloid-like glucagon fibrils

Journal of Diabetes Science and Technology

Volumn 4, Issue 6, 2010, Pages 1357-1367

  Pedersen, Jesper Søndergaard ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aggregation; Amyloid; Cyclodextrins; Drug formulation; Excipients; Fibrils; Glucagon

Indexed keywords

AMYLOID; GLUCAGON;

ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG STABILITY; HUMAN; KINETICS; METABOLISM; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

AMYLOID; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; GLUCAGON; HUMANS; KINETICS; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 79953010384     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400609     Document Type: Conference Paper

References (80)

1. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab. 2003;284(4):E671-8.
2. Elrick H, Witten TA, Arai Y. Glucagon treatment of insulin reactions. N Engl J Med. 1958;258(10):476-80.
3. Hradsky M, Stockbrugger R, Dotevall G, Ostberg H. The use of glucagon during upper gastrointestinal endoscopy. Gastrointest Endosc. 1974;20(4):162.
4. Staub A, Sinn L, Behrens OK. Purification and crystallization of glucagon. J Biol Chem. 1955;214(2):619-32.
5. King MV. A low-resolution structural model for cubic glucagon based on packing of cylinders. J Mol Biol. 1965;11:549-61.
6. Sasaki K, Dockerill S, Adamiak DA, Tickle IJ, Blundell T. X-ray analysis of glucagon and its relationship to receptor binding. Nature. 1975;257(5529):751-7.
7. Panijpan B, Gratzer WB. Conformational nature of monomeric glucagon. Eur J Biochem. 1974;45(2):547-53.
8. Gratzer WB, Beaven GH, Rattle HW, Bradbury EM. A conformational study of glucagon. Eur J Biochem. 1968;3(3):276-83.
9. Onoue S, Yamamoto K, Kawabata Y, Hirose M, Mizumoto T, Yamada S. Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery. Int J Pharm. 2009;382(1-2):144-50.
10. Swann JC, Hammes GG. Self-association of glucagon. Equilibrium studies. Biochemistry. 1969;8(1):1-7.
11. Gratzer WB, Creeth JM, Beaven GH. Presence of trimers in glucagon solution. Eur J Biochem. 1972;31(3):505-9.
12. Andersen CB, Otzen D, Christiansen G, Rischel C. Glucagon amyloid-like fibril morphology is selected via morphology-dependent growth inhibition. Biochemistry. 2007;46(24):7314-24.
13. Beaven GH, Gratzer WB, Davies HG. Formation and structure of gels and fibrils from glucagon. Eur J Biochem. 1969;11(1):37-42.
14. Moran EC, Chou PY, Fasman GD. Conformational transitions of glucagon in solution: the alpha to beta transition. Biochem Biophys Res Commun. 1977;77(4):1300-6.
15. Glenner GG, Eanes ED, Bladen HA, Linke RP, Termine JD. Beta-pleated sheet fibrils. A comparison of native amyloid with synthetic protein fibrils. J Histochem Cytochem. 1974;22(12):1141-58.
16. Masters CL, Beyreuther K. Pathways to the discovery of the Abeta amyloid of Alzheimer's disease. J Alzheimers Dis. 2006; 9(3 Suppl):155-61.
17. Prusiner SB. Molecular biology of prion diseases. Science. 1991;252(5012):1515-22.
18. Aguzzi A, Haass C. Games played by rogue proteins in prion disorders and Alzheimer's disease. Science. 2003;302(5646):814-8.
19. Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. Embo J. 2008;27(2):336-49.
20. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging. 2006;27(4):570-5.
21. Wyttenbach A. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis. J Mol Neurosci. 2004;23(1-2):69-96.
22. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267-98.
23. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science. 2006;313(5793):1604-10.
24. Otzen DE, Nielsen PH. We find them here, we find them there: Functional bacterial amyloid. Cell. Mol. Life Sci. 2008;65(4612): 910-927.
25. Fowler DM, Koulov AV, Balch WE, Kelly JW. Functional amyloid - from bacteria to humans. Trends Biochem Sci. 2007;32(5):217-24.
26. Braun W, Wider G, Lee KH, Wuthrich K. Conformation of glucagon in a lipid-water interphase by 1H nuclear magnetic resonance. J Mol Biol. 1983;169(4):921-48.
27. Ying J, Ahn JM, Jacobsen NE, Brown MF, Hruby VJ. NMR solution structure of the glucagon antagonist [desHis1, desPhe6, Glu9] glucagon amide in the presence of perdeuterated dodecylphosphocholine micelles. Biochemistry. 2003;42(10):2825-35.
28. Pedersen JS, Otzen DE. Amyloid a state in many guises: survival of the fittest fibril fold. Protein Sci. 2008;17(1):2-10.
29. Epand RM. Cation-induced conformational change in glucagon. Mol Pharmacol. 1982;22(1):105-8.
30. Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, Singru PS, Nilsson KP, Simon R, Schubert D, Eisenberg D, Rivier J, Sawchenko P, Vale W, Rick R. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science. 2009;325(5938):328-32.
31. Maji SK, Schubert D, Rivier C, Lee S, Rivier JE, Riek R. Amyloid as a depot for the formulation of long-acting drugs. PLoS Biol. 2008;6(2):e17.
32. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, Kashimoto K, Yajima T. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res. 2004;21(7):1274-83.
33. Chien P, Weissman JS, DePace AH. Emerging principles of conformation-based prion inheritance. Annu Rev Biochem. 2004;73:617-56.
34. Kodali R, Wetzel R. Polymorphism in the intermediates and products of amyloid assembly. Curr Opin Struct Biol. 2007;17(1):48-57.
35. Dzwolak W, Smirnovas V, Jansen R, Winter R. Insulin forms amyloid in a strain-dependent manner: an FT-IR spectroscopic study. Protein Sci. 2004;13(7):1927-32.
36. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science. 2005;307(5707):262-5.
37. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, Relini A, Stefani M, Dobson CM, Cecchi C, Chiti F. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol. 2010;6(2):140-7.
38. Yoshiike Y, Akagi T, Takashima A. Surface structure of amyloid-beta fibrils contributes to cytotoxicity. Biochemistry. 2007;46(34):9805-12.
39. Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol. 2006;355(3):501-23.
40. Pedersen JS, Flink JM, Dikov D, Otzen DE. Sulfates dramatically stabilize a salt-dependent type of glucagon fibrils. Biophys J. 2006;90(11):4181-94.
41. Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95(23):13363-83.
42. Toyama BH, Kelly MJ, Gross JD, Weissman JS. The structural basis of yeast prion strain variants. Nature. 2007;449(7159):233-7.
43. Jeppesen MD, Hein KL, Nissen P, Westh P, Otzen D. A thermodynamic analysis of fibrillar polymorphism. Biophys Chem. 2010; in press.
44. Andersen CB, Hicks MR, Vetri V, Vandahl B, Rahbek-Nielsen H, Thogersen H, Enghild JJ, Serpell LC, Rischel C, Otzen DE. Glucagon fibril polymorphism reflects differences in protofilament backbone structure. J Mol Biol. 2010;397(4):932-46.
45. Pedersen JS, Andersen CB, Otzen D. Amoloid structure - one but not the same: the many levels of glucagon polymorphism. Febs J. 2010;DOI: 10.1111/j.1742-4658.2010.07888.x (Forthcoming).
46. Jeppesen MD, Westh P, Otzen DE. The role of protonation in protein fibrillation. FEBS Lett. 2010;584(4):780-784.
47. Morris AM, Watzky MA, Finke RG. Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. Biochim Biophys Acta. 2009;1794(3):375-97.
48. LeVine H, 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274-84.
49. Bromer WW, Staub A, Diller ER, Bird HL, Sinn LG, Behrens OK. The amino acid sequence of glucagon. J Am Chem Soc. 1957;79:2794-8.
50. Vivian JT, Callis PR. Mechanisms of tryptophan fluorescence shifts in proteins. Biophys J. 2001;80(5):2093-109.
51. Ban T, Hamada D, Hasegawa K, Naiki H, Goto Y. Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J Biol Chem. 2003;278(19):16462-16465.
52. Ferkinghoff-Borg J, Fonslet J, Andersen CB, Krishna S, Pigolotti S, Yagi H, Goto Y, Otzen DE, Jensen MH. Stop-and-go kinetics in amyloid fibrillation. Available from Nature Proceedings 〈http://hdl.handle.net/10101/npre.2010. 4279.1〉
53. Ferrone F. Analysis of protein aggregation kinetics. Methods Enzymol. 1999;309:256-74.
54. Oliveira CL, Behrens MA, Pedersen JS, Erlacher K, Otzen D, Pedersen JS. A SAXS study of glucagon fibrillation. J Mol Biol. 2009;387(1):147-61.
55. Andersen CB, Yagi H, Manno M, Martorana V, Ban T, Christiansen G, Otzen DE, Goto Y, Rischel C. Branching in amyloid fibril growth. Biophys J. 2009;96(4):1529-36.
56. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol. 1998;8(1):101-6.
57. Hoppe CC, Nguyen LT, Kirsch LE, Wiencek JM. Characterization of seed nuclei in glucagon aggregation using light scattering methods and field-flow fractionation. J Biol Eng. 2008;2:10.
58. Svane AS, Jahn K, Deva T, Malmendal A, Otzen DE, Dittmer J, Nielsen NC. Early stages of amyloid fibril formation studied by liquid-state NMR: the peptide hormone glucagon. Biophys J. 2008;95(1):366-77.
59. Banga AK, Mitra R. Minimization of shaking-induced formation of insoluble aggregates of insulin by cyclodextrins. J Drug Target. 1993;1(4):341-5.
60. Collins SR, Douglass A, Vale RD, Weissman JS. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol. 2004;2(10):e321.
61. Pedersen JS. In Vitro Studies of Amyloid-Like Protein Fibrils Using Glucagon as Model System [PhD Thesis]. Aalborg: Aalborg University; 2006.
62. Hall D, Edskes H. Silent prions lying in wait: a two-hit model of prion/amyloid formation and infection. J Mol Biol. 2004;336(3): 775-86.
63. Paravastu AK, Leapman RD, Yau WM, Tycko R. Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci USA. 2008;105(47):18349-54.
64. Loksztejn A, Dzwolak W. Vortex-induced formation of insulin amyloid superstructures probed by time-lapse atomic force microscopy and circular dichroism spectroscopy. J Mol Biol. 2010;395(3):643-55.
65. Makarava N, Baskakov IV. The same primary structure of the prion protein yields two distinct self-propagating states. J Biol Chem. 2008;283(23):15988-96.
66. Sluzky V, Tamada JA, Klibanov AM, Langer R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci U S A. 1991;88(21): 9377-81.
67. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006;55(12):3344-50.
68. Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, Ward WK. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010.
69. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2(27):27.
70. Findeis MA. Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem. 2002;2(4):417-23.
71. Sato T, Kienlen-Campard P, Ahmed M, Liu W, Li H, Elliott JI, Aimoto S, Constantinescu SN, Octave JN, Smith SO. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry. 2006;45(17):5503-16.
72. Pedersen JS, Dikov D, Otzen DE. N- and C-terminal hydrophobic patches are involved in fibrillation of glucagon. Biochemistry. 2006;45(48):14503-12.
73. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. 2005;6(2):E329-57.
74. Otzen DE, Knudsen BR, Aachmann F, Larsen KL, Wimmer R. Structural basis for cyclodextrins' suppression of human growth hormone aggregation. Protein Sci. 2002;11(7):1779-87.
75. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98(5):2045-76.
76. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86(2):147-62.
77. Thompson DO. Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst. 1997;14(1):1-104.
78. Sakr FM. Nasal administration of glucagon combined with dimethyl-[beta]-cyclodextrin: Comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations. International Journal of Pharmaceutics. 1996;132(1-2):189-194.
79. Matilainen L, Larsen KL, Wimmer R, Keski-Rahkonen P, Auriola S, Jarvinen T, Jarho P. The effect of cyclodextrins on chemical and physical stability of glucagon and characterization of glucagon/gamma-CD inclusion complexes. J Pharm Sci. 2008;97(7):2720-9.
80. Matilainen L, Maunu SL, Pajander J, Auriola S, Jaaskelainen I, Larsen KL, Jarvinen T, Jarho P. The stability and dissolution properties of solid glucagon/gamma-cyclodextrin powder. Eur J Pharm Sci. 2009;36(4-5):412-20.